Fimasartan Blood Pressure Lowering After Acute Stroke "FABULOUS"

Recruiting

Phase N/A Results N/A

Trial Description

This study evaluates the effectiveness of fimasartan-based antihypertensive treatment and prognosis in post-acute phase of ischemic stroke or transient ischemic attack patients. All participants will receive fimasartan, and the investigators will follow them up for 6 months.

Conditions

Trial Population

1,032 subjects of post-acute phase of ischemic stroke or transient ischemic attack patients

Outcomes

Type Measure Time Frame Safety Issue
Primary Blood pressure control rate(<140/90 mmHg) 24 weeks
Secondary Blood pressure changes 4, 12, 24 weeks
Secondary mRS changes 4, 12, 24 weeks
Secondary Fimasartan-based treatment modalities 24 weeks
Secondary Fimasartan starting point after stroke 24 weeks
Secondary Rate of stroke recurrence 24 weeks
Secondary Incidence of cardiovascular events 24 weeks
Secondary Mortality rates from cardiovascular disease 24 weeks
Secondary Mortality rates of any cause 24 weeks
Secondary Adverse events related to antihypertensive treatments 24 weeks

Sponsors